Increase of the antitumour efficacy of the biocompound IMMUNEPOTENT CRP by enzymatic treatment by Franco Molina, Moisés Armides et al.
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=tbeq20
Biotechnology & Biotechnological Equipment
ISSN: 1310-2818 (Print) 1314-3530 (Online) Journal homepage: https://www.tandfonline.com/loi/tbeq20
Increase of the antitumour efficacy of the
biocompound IMMUNEPOTENT CRP by enzymatic
treatment
Moises A. Franco-Molina, Silvia E. Santana-Krímskaya, Erika E. Coronado-
Cerda, Carlos Eduardo Hernández-Luna, Diana G. Zarate-Triviño, Pablo
Zapata-Benavides, Edgar Mendoza-Gamboa, María C. Rodríguez-Salazar,
Reyes Tamez-Guerra & Cristina Rodríguez-Padilla
To cite this article: Moises A. Franco-Molina, Silvia E. Santana-Krímskaya, Erika E. Coronado-
Cerda, Carlos Eduardo Hernández-Luna, Diana G. Zarate-Triviño, Pablo Zapata-Benavides, Edgar
Mendoza-Gamboa, María C. Rodríguez-Salazar, Reyes Tamez-Guerra & Cristina Rodríguez-
Padilla (2018) Increase of the antitumour efficacy of the biocompound IMMUNEPOTENT CRP
by enzymatic treatment, Biotechnology & Biotechnological Equipment, 32:4, 1028-1035, DOI:
10.1080/13102818.2018.1460622
To link to this article:  https://doi.org/10.1080/13102818.2018.1460622
© 2018 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 09 Apr 2018.
Submit your article to this journal Article views: 322
View Crossmark data Citing articles: 1 View citing articles 
ARTICLE; PHARMACEUTICAL BIOTECHNOLOGY
Increase of the antitumour efﬁcacy of the biocompound IMMUNEPOTENT CRP by
enzymatic treatment
Moises A. Franco-Molinaa, Silvia E. Santana-Krımskayaa, Erika E. Coronado-Cerdaa,
Carlos Eduardo Hernandez-Lunab, Diana G. Zarate-Trivi~noa, Pablo Zapata-Benavidesa, Edgar Mendoza-Gamboaa,
Marıa C. Rodrıguez-Salazara, Reyes Tamez-Guerraa and Cristina Rodrıguez-Padillaa
aDepartment of Microbiology and Immunology, Faculty of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolas De Los
Garza, Mexico; bDepartment of Biochemistry, Faculty of Biological Sciences, Autonomous University of Nuevo Leon, San Nicolas De Los Garza,
Mexico
ARTICLE HISTORY
Received 3 September 2017
Accepted 30 March 2018
ABSTRACT
IMMUNEPOTENT CRP is a dialyzable leukocyte extract obtained from bovine spleen with
immunomodulatory and antitumour properties; therefore, when administrated as an adjuvant
therapy for cancer patients, it has increased their survival and quality of life. The bioavailability of
any orally administered compound can be reduced due to gastrointestinal enzymes. In this study,
we evaluated if IMMUNEPOTENT CRP is resistant to the treatment with different enzymes
(proteases, nucleases, polysaccharide-degrading enzymes or lipase), using as parameters for
biological activity measurement its in vitro antitumour and antioxidant properties and in vivo the
antitumour effect of IMMUNEPOTENT CRP treated with proteinase K. In conclusion, we consider
necessary to include the antioxidant and cytotoxic activity on the MCF-7 cancer cell line as
parameters for the quantitative determination of biological activity or potency tests for batch
release. Additionally, the results showed that different enzymatic treatments do not affect the
antitumour and antioxidant activities of IMMUNEPOTENT CRP in vitro, suggesting that this product
can be administered orally without any loss of biological activity. Furthermore, IMMUNEPOTENT
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Introduction
In 1955, doctor Sherwood Lawrence described for the
ﬁrst time that delayed type IV hypersensitivity can be
transferred from an immunocompetent individual to a
naive recipient by administration of a dialyzable leuko-
cyte extract (DLE). Lawrence termed the unknown mole-
cule or group of molecules responsible for this effect
‘transfer factor’ [1]. The dialyzable extract (DLE) is a het-
erogeneous mixture of substances resulting from the
disruption and dialysis (<12 kDa) of leukocytes into an
aqueous solution. It is derived from different sub-popula-
tions of leukocytes, each one with different functions
and molecules; therefore the DLE has many biological
effects on the immune system, not all of them immunity
transference related [2]. Due to its immunomodulatory
properties, the DLE containing transfer factor has been
used for the treatment of many immune system related
pathologies and cancer [3]. Immunotherapy has become
one of the standard treatments for cancer; therefore
immunomodulatory and adjuvant substances are being
investigated for this purpose, biological compounds
included. However, it is important to optimize their for-
mulation to guarantee efﬁcacy, safety, and stability in
any form of administration [4,5]. IMMUNEPOTENT CRP
(ICRP) is a biological compound obtained from the dis-
ruption of bovine spleen leukocytes containing transfer
factor with versatile activities. It has been proved to
modulate cytokine production [6], increase the number
of immunocompetent cells (CD4+, CD8+, CD56+) [7], pro-
tect the bone marrow from aggressive side effects of
chemotherapy [8] and induce differentiation of leukemia
blast cells [9]. In vitro studies also show that ICRP is toxic
to cancer cell lines [10] and has strong antioxidant prop-
erties [6]. Overall its administration as an adjuvant ther-
apy to patients with cancer improves their quality of life
and survival [7,11]. In addition to its efﬁcacy, ICRP is
reported free of adverse effects in humans. It is a non-
pyrogenic substance, with no HLA antigens and it can
be lyophilized and stored for a long time without losing
its biological properties [10]. However, there is a lack of
information regarding the potential degradation of ICRP
or any other DLE once it is administered into the body
[12]. The most desirable route of administration for any
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drug therapy is oral, particularly for the treatment of
chronic conditions. But many compounds are suscepti-
ble to the conditions of the gastrointestinal tract. There-
fore, any biological compound should be exposed to
conditions that may compromise the quality and stabil-
ity, for example, low pH and hydrolytic enzymes, and
tested for any activity decrease [13]. In the present study,
we focused on the resistance of the ICRP to enzymatic
treatment over a speciﬁc type of biomolecule (proteins,
lipids, carbohydrates or nucleic acids) using the antioxi-
dant and antitumour in vitro properties of ICRP as
potency tests of biological activity. Furthermore, we
tested the antitumour properties of ICRP and ICRP
treated with proteinase K in vivo. The information
obtained will contribute to improve the ICRP formulation




ICRP was produced by the Laboratory of Immunology
and Virology, Faculty of Biological Sciences, University
Autonomous of Nuevo Leon (UANL) (San Nicolas de los
Garza, Mexico). ICRP is dialyzed, lyophilized and pyro-
gen-free. One unit of ICRP has been deﬁned as the prod-
uct obtained from 15 £ 108 bovine spleen cells.
Enzymes
The following enzymes were used in this study. Pro-
teases: Collagenase (Sigma, Chemical Company, St. Louis
MO, USA), pepsin (0.8% pepsin, 0.2 N HCl) (DAKO, S~ao
Paulo, Brasil), neutral protease (Worthington Biochemical
Corporation, Lakewood, New Jersey, USA), proteinase K
(MP Biomedical, Santa Ana, California, USA), trypsin
(Sigma, Chemical Company, St. Louis MO, USA) and vali-
dase (Valley Research). Nucleases: deoxyribonuclease I
(Sigma, Chemical Company, St. Louis MO, USA) and ribo-
nuclease A (US Biologicals Salem, Massachusetts, USA).
Polysaccharide degrading enzymes: a-amylase (Sigma,
Chemical Company, St. Louis MO, USA) and lysozyme
(MP Biomedical, Santa Ana, California, USA). Lipase: lipo-
zyme (Novo Industrials, Copenhagen, Denmark).
Cell lines
Breast carcinoma MCF7 (ATCC® HTB-22TM) cell line was
obtained from ATCC (American Type Culture Collection,
Manassas, VA, USA) and cultured in DMEM medium with
10% bovine serum and 1% of antimycotic-antibiotic
(penicillin, streptomycin and amphotericin B) (Sigma,
Chemical Company, St. Louis MO, USA), and incubated in
atmosphere with 5% CO2 at 37 C. Murine lymphoma
cell line L5178-R (LY-R) (ATCC® CRL-1722TM) was
obtained from ATCC (American Type Culture Collection,
Manassas, VA. USA) and maintained as transplantable
ascites tumour in BALB/c mice. The pattern of tumour
growth was consistent and reproducible.
Animals
Female (6–8 weeks old) BALB/c mice housed in separate
stainless steel cages (5 mice per cage) at constant tem-
perature (25 C) with light and dark cycles of 12 h, access
to water and feed ad libitum with rodent balanced diet
(Harlan Teklad). All procedures of this study were
approved by the Animal Bioethics Committee of the Lab-
oratory of Immunology and Virology of the Biological
Sciences Faculty of the National University of Nuevo
Leon (CEIBA).
Determination of proteases enzymatic activity
To conﬁrm the proteases enzymatic activity, an ovalbu-
min solution (Sigma, Chemical Company, St. Louis MO,
USA) was prepared and allotted as follows: ovalbumin,
ovalbumin with collagenase, ovalbumin with pepsin,
ovalbumin with neutral protease, ovalbumin with pro-
teinase K, ovalbumin with trypsin and ovalbumin with
validase. The aliquots were incubated at 37 C for 2 h
and protein concentration was determined by the DCTM
Protein Assay (BIO-Rad, Hercules, California, U.S.A.).
Determination of nucleases enzymatic activity
To conﬁrm the nucleases enzymatic activity, we
extracted plasmid DNA from E. coli DH5-Alpha following
the Ausbel minipreparation protocol with a minor modi-
ﬁcation: we did not add the RNase into the preparation
to obtain bacterial RNA as well. The resultant nucleic
acid preparation was quantiﬁed by spectrophotometry
using the NanoDropTM 2000 (Life Technologies; Thermo
Fisher Scientiﬁc, Inc., Waltham, MA, USA) and allotted as
follows: nucleic acid preparation, nucleic acid prepara-
tion with DNAse, nucleic acid preparation with RNase
and nucleic acid preparation with DNAse and RNase. All
aliquots were incubated at room temperature (25 C) for
10 min, followed by electrophoresis in agarose gel
(0.8%) and ethidium bromide staining (10 mg/mL). Uni-
versal Hood II Electrophoresis Imaging Cabinet (BIO-Rad,
Hercules, California, U.S.A.) was used for gel visualization
and imaging.
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Determination of polysaccharide-degrading
enzymes activity
To conﬁrm the a-amylase activity, we prepared agar
(0.15 g) (BD Biosciences) with starch (0.1 g) in 10 mL of
ultrapure water and poured the preparation in 2 plates
of 3 cm diameter (2 mL per plate). Once the agar solidi-
ﬁed, we added a-amylase (1 mg/mL) to one of the plates.
Both plates were incubated at 37 C for 1 h and stained
with Lugol (100 mL). To conﬁrm the activity of lysozyme,
we prepared agar (0.15 g) (BD Biosciences) with lyophi-
lized Micrococcus lysodeikticus (0.1 g) in 10 mL of ultra-
pure water and poured the preparation in 2 plates of
3 cm diameter (2 mL per plate). Once the agar solidiﬁed,
we added lysozyme to one of the plates, and both plates
were incubated at 37 C for 1 h. Clear zones in the agar
indicated lysozyme activity.
Determination of lipase activity
To conﬁrm the lipozyme activity, we prepared agar
(0.15 g) (BD Biosciences) with oil (2 mL) in 10 mL of ultra-
pure water, and poured the preparation in 2 plates of
3 cm diameter (2 mL per plate). Once the agar solidiﬁed,
we added lipozyme to one of the plates. Both plates
were incubated at 37 C for 1 h and stained with Sudan
III (Sigma, Chemical Company, St. Louis MO, USA).
IMMUNEPOTENT CRP treatment with enzymes
Several aliquots of ICRP (5 units) were diluted in DMEM
medium (1 mL). Each aliquot was then treated for 24 h
with a speciﬁc enzyme at the pH, concentration and
temperature established by the manufacturer as
described in Table 1. Finally, all aliquots were heated in a
water bath at 100 C for 10 min to inactivate the
enzymes, pH was adjusted to 7, and ICRP was diluted to
a ﬁnal concentration of 2 units/mL in DMEM medium
supplemented with fetal bovine serum (10%).
Cell viability assay
The dose–response curve of ICRP-treated MCF7 cancer
cell line was obtained by the resazurin assay (Resazurin
sodium salt; Sigma Chemical Company, St. Louis MO,
USA). MCF7 cells were seeded in a 96-well plate at a den-
sity of 5000 cells per well and incubated at 37 C in 5%
CO2 atmosphere for 24 h. The cells were exposed to dif-
ferent concentrations of IMMUNEPOTENT CRP treated or
not treated with enzymes (0.2–2.0 units/mL) and incu-
bated at 37 C in 5% CO2 atmosphere for 24 h. The
medium was removed and 100 mL of DMEM supple-
mented with 10% bovine serum and 20 mL of resazurin
were added. The plate was incubated at 37 C in 5% CO2
atmosphere for 12 h. The ﬂuorescence was measured at
530 nm excitation wavelength and 590 nm emission
wavelength with the Synergy HTTM (BioTek Instruments,
Inc., Winooski, VT, USA) plate reader.
MTT antioxidant assay
Aliquots of 200 mL/well of IMMUNEPOTENT CRP treated
or not treated with enzymes were pipetted to a 96-well
plate and 100 mL of 3-(4,5-dimethylthiazol-2-yl)¡2,5-
diphenyltetrazolium bromide [MTT] (1 mg/mL) were
added. The reaction mixture was then incubated at
37 C for 2 h, and the absorbance was measured at
570 nm wavelength with the Synergy HTTM (BioTek
Instruments, Inc., Winooski, VT, USA) plate reader. Each
sample was assayed in triplicate.
Modiﬁed mouse air pouch model for evaluation of
the antitumour activity of IMMUNEPOTENT CRP
Air pouches were formed as described by Gaspar et al.
[14], with modiﬁcations. Brieﬂy, 5 mL of sterile air were
injected subcutaneously into the shaved back of the
mice; after 3 days, another 3 mL of sterile air were
injected once again into the back of the animals. Three
days later, L5178Y-R viable cells (2 £ 106 in 0.5 mL of
PBS) were injected subcutaneously into the air pouch of
every mouse and these were randomly divided into 5
groups (n = 3, each group) for therapy administration:
PBS (group 1), 5-ﬂuorouracil (20 mg/kg) (group 2), ICRP –
3 units (group 3), ICRP – 5 units (group 4) and ICRP
treated with proteinase K (group 5). Therapy began on
the same day of L-5178Y-R tumour cells inoculation; all
treatments were administered daily for 9 days into the
air pouch. The day after the last injection, the mice were
anesthetized with an intraperitoneal injection of a solu-
tion containing 100–200 mg/kg mouse body weight of
ketamine and 5–16 mg/kg mouse body weight of
Table 1. Protocol of enzymatic treatment of IMMUNEPOTENT
CRP.
Enzyme Concentration pH Temperature (C) Time (h)
Collagenase 1 mg/mL 7.4 37 24
Pepsin 100 mL/mL 2.0 37 24
Neutral protease 5 mg/mL 7.5 37 24
Proteinase K 10 mg/mL 7.5 37 24
Trypsin 1 mg/mL 7.0 37 24
Validase 5 mg/mL 3.0 37 24
DNase I 70 units/mL 7.0 25 24
RNase A 3.75 mL/mL 7.6 37 24
a-amylase 1 mg/mL 6.9 40 24
Lysozyme 10 mg/mL 6.2 37 24
Lipozyme 4.3 mg/mL 8.0 55 24
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xylazine, and were sacriﬁced by cervical dislocation, as
approved by the Animal Research and Welfare Ethics
Committee of the Faculty of Biological Sciences (CEIBA)
of UANL. For therapy evaluation (observable tumour pro-
gression) the tumour foci and tumour weight were taken
into account.
Statistical data analysis
All experiments were performed in triplicate and are pre-
sented as average and standard deviation (§SD). Statisti-
cal analysis was performed using SPSS 22.0 statistical
software (SPSS, Inc., Chicago, IL, USA) and included anal-
ysis of variance followed by post hoc Dunnett's or Tukey
tests. Values of p < 0.05 were considered to indicate a
statistically signiﬁcant differences.
Results and discussion
IMMUNEPOTENT CRP has improved the overall condition
and life expectancy of cancer patients when adminis-
tered as an adjuvant therapy [11]. As with any other bio-
logical compound, the oral route is the most desirable
administration pathway [5]; however there are no
reports of the preservation or degradation of the biologi-
cal activities of IMMUNEPOTENT CRP once it is exposed
to the harsh conditions of the gastrointestinal tract, such
as low pH, changes in temperature and especially hydro-
lytic activity of enzymes. Other dialyzable leukocyte
extracts have been exposed to enzymatic treatments in
the past, and the reported results vary [15,16]. By means
of these studies, the authors suggested that the immu-
nity transference is RNA related and that the in vitro
rosette formation is due to the protein fraction from the
extract [15,16]. The enzymes used in these studies were
nucleases and proteases only, and no other biological
activities were evaluated. In the present study, we
exposed IMMUNEPOTENT CRP to the hydrolytic activity
of proteases (collagenase, pepsin, neutral protease, pro-
teinase K, trypsin and validase), nucleases (DNAse I and
RNase A), polysaccharide-degrading enzymes (a-amylase
and lysozyme) and a lipase (lipozyme).
To conﬁrm that our enzymes were active, we tested
them over their known substrates. For evaluation of pro-
teases functionality, we used ovalbumin (5 mg/mL) as
our protein substrate, ﬁnding a highly signiﬁcant (**p <
0.01) decrease in the ovalbumin concentration depen-
dent on the enzymatic treatment: collagenase (2.39 mg/
mL), pepsin (1.80 mg/mL), proteinase K (1.95 mg/mL),
neutral protease (1.28 mg/mL), trypsin (1.67 mg/mL) and
validase (1.62 mg/mL) compared with control (untreated
ovalbumin) (5 mg/mL) (Figure 1). For nucleases (DNase I
and RNase A) evaluation, we employed plasmid DNA
and bacterial RNA as nucleic acid substrates, observing
degradation of both substrates by their respective
enzymes (Figure 2). To determine the functionality of
a-amylase, we evaluated the degradation of starch by
lugol staining (Figure 3), and for lysozyme, the degrada-
tion of lyophilized M. lysodeikticus by change of turbidity
(Figure 4). We observed substrate degradation in both
cases. To test the lipozyme functionality, we used agar
with oil emulsions and corroborated the substrate degra-
dation by Sudan III staining (Figure 5). According to our
results, all enzymes used in the present study were
functional.
MCF7 cells were exposed to heat-inactivated enzymes
using the same concentrations as the ones used with
IMMUNEPOTENT CRP. There was no signiﬁcant differ-
ence (P < 0.05) between the viability of the treated and
non-treated MCF7 cells (Table 2), corroborating that
Figure 1. Protease activity evaluation.
Note: Ovalbumin solution (5 mg/mL) was incubated with different proteases at 37 C for 2 h. Values are means from three independent experiments. **P < 0.01,
signiﬁcant difference (post hoc Dunnet test).
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heat-inactivated enzymes do not affect MCF7 cells
viability.
IMMUNEPOTENT CRP treated with enzyme or not
treated decreased the viability of MCF7 cells in a dose-
dependent manner (p < 0.05) (Table 3). However, there
were signiﬁcant differences (p < 0.05) in the lethal doses
obtained at the concentrations of LD25 (1 U/mL) and
LD50 (1.2 U/mL) between treatments. IMMUNEPOTENT
CRP treated with proteinase K showed an increased anti-
tumour activity when compared to non-treated IMMU-
NEPOTENT CRP (*p < 0.05). According to Segura-
Campos et al. [17], enzymatic digestion can liberate frag-
ments with higher biological activity than the precursor
compound. There were no signiﬁcant differences (*p
< 0.05) in the cellular viability decrease at the absolute
lethal dose, LD100 (1.8 U/mL), between treatments
(Table 3).
Regarding the antioxidant activity, there was a signiﬁ-
cant difference (*p < 0.05) between the DMEM medium
and the IMMUNEPOTENT CRP treated or not with
enzymes. However, there was no signiﬁcant difference
(*P < 0.05) in the antioxidant activity values between
IMMUNEPOTENT CRP treated and not treated with
enzyme (Figure 6).
Our results showed that the in vitro biological activi-
ties (antitumour and antioxidant) of IMMUNEPOTENT
CRP are resistant to the enzymatic treatments used. This
study is important because the bioavailabiltiy of com-
pounds administered by the oral route can be limited
due to pre-systemic metabolism by hydrolytic activity of
enzymes present the gastrointestinal tract, resulting in a
Figure 2. Nuclease activity evaluation.
Note: Agarose gel (0.8%) electrophoresis and bromide ethidium staining
(10 mg/mL) of plasmid DNA and bacterial RNA treated with DNase I and
RNase A, respectively.
Figure 3. a-Amylase activity evaluation.
Note: Agar containing starch (A) and agar containing starch treated with
a-amylase (B) were prepared and incubated for 1 h at 37 C and stained with
Lugol (100 mL) evidencing starch presence in the agar not treated with
a-amylase (C) and starch degradation in the agar treated with the enzyme
(D).
Figure 4. Lysozyme evaluation activity.
Note: Agar containing lyophilized M. lysodeikticus (A) and agar containing
lyophilized M. lysodeikticus and treated with lysozyme (B) were prepared and
incubated for 2 h at 37 C. M. lysodeikticus degradation was evidenced by
change in the turbidity of the agar.
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reduced biological effect [18], such as reported by Kup-
ferschmidt et al. [19] and Tuteja et al. [20]. The bioavail-
ability of saquinavir and tacrolimus, respectively, was
less than 20% when administered by the oral route
[19,20]. Moreover, as part of our commercial production
strategy, we consider it necessary to include the antioxi-
dant and cytotoxic activity on the MCF-7 cancer cell line
as parameters for the quantitative determination of bio-
logical activity or potency tests for the batch release.
We also tested the in vivo antitumour activity of
IMMUNEPOTENT CRP and IMMUNEPOTENT CRP treated
with proteinase K, ﬁnding that the three units dose did
not affect the tumour foci and tumour weight when
Figure 5. Lipozyme activity evaluation.
Note: Agar containing oil emulsions (A) and agar containing oil emulsions
and treated with lipozyme (B) were prepared and incubated for 1 h at 37 C
and stained with Sudan III evidencing oil presence in the agar not treated
with lipozyme (C) and oil degradation in the agar treated with lipozyme (D).
Table 2. Effect of inactivated enzymes on the viability of MCF7
cells.
Viability (%)
Treatment LD25 (1 U/mL) LD50 (1.2 U/mL) LD100 (1.8 U/mL)
Control 100 § 1.72 100 § 3.49 98.28 § 0.07
Collagenase 99.63 § 5.02 98.67 § 3.1 98.32 § 0.38
Neutral protease 98.03 § 1.15 100 § 2.14 100 § 3.62
Pepsin 97.65 § 1.61 99.74 § 2.53 99.14 § 0.64
Proteinase K 100 § 4.20 97.35 § 3.10 97.56 § 2.61
Trypsin 100 § 2.92 98.87 § 1.74 100 § 1.54
Validase 100 § 2.38 98.5 § 1.86 97.63 § 1.33
DNAse I 95.18 § 2.00 99.76 § 1.81 98.85 § 2.15
RNAse A 99.25 § 0.88 94.31 § 4.04 100 § 2.42
a-amylase 100 § 3.92 99.89 § 1.82 100 § 1.33
Lysozyme 99.22 § 1.09 97.40 § 0.9 99.88 § 2.25
Lipozyme 97.99 § 1.44 97.85 § 3.42 98.90 § 3.19
Table 3. In vitro antitumour effect of IMMUNEPOTENT CRP
treated and not treated with enzyme on MCF7 cell line viability.
Viability (%)
Treatment LD25 (1 U/mL) LD50 (1.2 U/mL) LD100 (1.8 U/mL)
ICRP 73 § 1.72 43.47 § 3.49 0.14 § 0.07
ICRP + collagenase 62.29 § 5.02* 52.14 § 7.1 1.07 § 0.38
ICRP + neutral
protease
55.23 § 4.33* 32.43 § 4.07* 1 § 0.09
ICRP + pepsin 66.38 § 1.72* 38 § 3.49* 0.58 § 0.06
ICRP + proteinase K 19.38 § 4.92*a 11.10 § 1.53*a 1.07 § 0.66
ICRP + trypsin 64.4 § 1.72* 23.13 § 3.49* 1.3 § 0.06
ICRP + validase 78.51 § 3.36 64.49 § 4.41* 0.77 § 0.179
ICRP + DNase I 30.15 § 0.84* 27.14 § 1.06* 1.01 § 0.37
ICRP + RNase A 35.38 § 2.08* 25.32 § 0.73* 1.07 § 0.38
ICRP + a-amylase 75.49 § 3.52 31.78 § 3.55* 1.23 § 1.17
ICRP + lysozyme 78.38 § 4.65 52.59 § 3.94 0.41 § 0.27
ICRP + lipozyme 39.53 § 4.43* 22.38 § 2.67* 0.73 § 0.42
* P < 0.05.
Figure 6. Antioxidant effect of IMMUNEPOTENT CRP exposed and not exposed to enzymatic treatment.
Note: Each sample was assayed in triplicate. Values are means from three independent experiments. * P < 0.05, signiﬁcant difference (post hoc Dunnet test).
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compared with PBS treatment. However, IMMUNEPO-
TENT CRP (5 units dose) delayed tumour progression in a
similar manner as the chemotherapeutic agent 5-FU,
and IMMUNEPOTENT CRP treated with proteinase K (5
units dose) prevented the formation of any tumour foci
during the evaluation period (Figures 7 and 8). In a previ-
ous report, we achieved similar results (a 50% tumour
reduction) in a melanoma mice model using IMMUNE-
POTENT CRP [21]. It would be interesting to corroborate
the antitumour effect of IMMUNEPOTENT CRP treated
with proteinase K on this model as well.
Conclusions
The results from this study showed that the antioxidant
and antitumour biological activities of IMMUNEPOTENT
CRP, are resistant to enzymatic treatment with proteases,
nucleases, polysaccharide-degrading enzymes and
lipases. Furthermore, IMMUNEPOTENT CRP treated with
proteinase K can be used to improve and optimise our
product formulation for cancer treatment. For this rea-
son, more clinical studies should be performed.
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